Premium
TD‐P‐19: DIGITIZING BRAIN HEALTH: FROM NEURODIFFERENTIATION TO DAILY ACTIVITIES
Author(s) -
Qutub Amina Ann,
Pollet Erin,
Long Byron,
Mahadevan Arun,
Britton George
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4330
Subject(s) - induced pluripotent stem cell , neuroscience , wearable computer , cognition , medicine , profiling (computer programming) , physical activity , neural stem cell , biology , stem cell , computer science , physical medicine and rehabilitation , biochemistry , embryonic stem cell , genetics , gene , embedded system , operating system
mutation carriers, and four controls. Mann-Whitney tests were used to compare performance of carriers against controls. Results: Presymptomatic carriers were significantly slower than controls at performing a number of tasks: Colour Mix Level 1 [a version of the Stroop task; p1⁄4 0.019], and Path Finder Level 1 [an adaptation of the Trail Making Test, p1⁄4 0.033]. Presymptomatic carriers also scored significantly lower than controls on a naming task [Name Game] [p1⁄40.025]. Symptomatic carriers were significantly slower and completed significantly fewer items than controls on eight of the tasks. Conclusions: In a preliminary analysis we show that the performance of presymptomatic mutation carriers is significantly worse than controls across a number of assessments using this novel cognitive assessment tool. Testing so far shows that the use of Ignite is feasible and can be self-administered by both presymptomatic and symptomatic participants. It has the potential to be more sensitive to cognitive decline than existing assessments. To our knowledge this is the only app to date designed specifically for genetic FTD and preliminary findings suggest that Ignite has the potential to be used in clinical trials as a primary outcome measure.